Edition:
United States

Alere Inc (ALR.N)

ALR.N on New York Stock Exchange

38.78USD
2:51pm EDT
Change (% chg)

$-0.41 (-1.05%)
Prev Close
$39.19
Open
$39.19
Day's High
$39.19
Day's Low
$38.68
Volume
46,968
Avg. Vol
126,551
52-wk High
$50.91
52-wk Low
$31.47

Latest Key Developments (Source: Significant Developments)

Alere provides update on Arriva Medical
Thursday, 9 Mar 2017 07:38pm EST 

Alere Inc : Alere provides update on Arriva Medical . Disagree with court's ruling on Arriva's motion for interim relief . Is considering options for appeal .Continues to provide patients with supplies they need as administrative appeal process proceeds.  Full Article

Alere receives FDA CLIA waiver for Alere i RSV rapid molecular test
Tuesday, 7 Mar 2017 07:00am EST 

Alere Inc - : Alere receives FDA CLIA waiver for Alere™ i RSV rapid molecular test .Alere i RSV test has been granted clinical laboratory improvement amendments waiver by FDA for detection of RSV infection in children & adults.  Full Article

Alere Inc files for non-timely 10-K
Wednesday, 1 Mar 2017 06:42am EST 

Alere Inc : Alere Inc - Files for non-timely 10-K - SEC filing . Alere - unable to file 10-K within prescribed time period because co is reviewing certain aspects of revenue recognition at Korean, Japanese locations . Alere- Management recently became aware of information that could impact timing of certain revenue transactions in 2013, 2014, 2015, first 3 quarters of 2016 . Alere- As part of revenue recognition review, reviewing inappropriate conduct at company’s subsidiary in South Korea, Standard Diagnostics, Inc . Alere - till revenue recognition review being conducted is not yet complete, currently expects that review will result in certain revenue adjustments . Alere - doesn't expect misstatements to impact total amount of revenue reported related to any transaction . Alere - correction of revenue amounts will result in a shift of revenue between accounting periods . Alere - not yet determined if correction of misstatements to require restatement, withdraw reliance on, issued financial statements for 2013, 2014, 2015 .Alere - not yet determined if correction of misstatements to require restatement, withdraw reliance on, issued financial statements for first 3 quarters of 2016.  Full Article

European Commission clears Abbott acquisition of Alere
Wednesday, 25 Jan 2017 11:00am EST 

Alere Inc : European Commission clears Abbott acquisition of Alere .Alere inc - "We remain highly confident that merger will close according to terms of agreement" with Abbott.  Full Article

Alere provides update on Arriva Medical
Wednesday, 28 Dec 2016 05:03pm EST 

Alere Inc : Alere provides update on Arriva Medical . Arriva has filed an appeal with administrative law judge (ALJ) at CMS seeking to reinstate Arriva's billing status . Alere Inc says expects a decision on its motions to enjoin on or about January 5, 2017 . Provided an update on decision by centers for Medicare & Medicaid services to revoke Arriva Medical's medicare billing privileges .Alere Inc- Arriva filed complaint seeking to compel CMS to stay process regarding competitive bidding contract termination while ALJ appeal is ongoing.  Full Article

Alere comments on Abbott's lawsuit
Wednesday, 7 Dec 2016 12:59pm EST 

Alere Inc : Alere issues statement regarding Abbott lawsuit . "Abbott's lawsuit is entirely without merit" . "Alere has fully complied with its contractual obligations under merger agreement" . Paul, Weiss, Rifkind, Wharton & Garrison and Cravath, Swaine & Moore LLP are serving as legal counsel to alere . Abbott well knows, none of issues it has raised provides it with any grounds to avoid closing merger . Alere will take all actions "to compel Abbott to complete transaction in accordance with its terms" ."Is highly confident that merger will be completed in accordance with terms set forth in merger agreement".  Full Article

Abbott says seeks to terminate Alere acquisition
Wednesday, 7 Dec 2016 11:14am EST 

Abbott Laboratories : Abbott seeks to terminate Alere acquisition . "Alere is no longer company Abbott agreed to buy 10 months ago" . In 10 months following Jan. 30, 2016, signing of agreement, Alere has "suffered a series of damaging business developments" . "We have attempted to secure details and information to assess these issues for months, and Alere has blocked every attempt" . Abbott filed its complaint seeking termination in delaware court of Chancery ."Damage to Alere's business can only be result of a systemic failure of internal controls".  Full Article

FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
Tuesday, 11 Oct 2016 12:41pm EDT 

U.S. FDA: Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio .FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation.  Full Article

Alere Q2 loss per share $0.46 from continuing operations
Tuesday, 6 Sep 2016 07:00am EDT 

Alere Says With Filing Of Q2 2016 Form 10 : Alere reports second quarter 2016 financial results . Q2 revenue $611 million versus I/B/E/S view $607.4 million . Q2 loss per share $0.46 from continuing operations . Q2 earnings per share view $0.58 -- Thomson Reuters I/B/E/S .Alere says with filing of Q2 2016 form 10-Q now current in financial filings and are on track to report our Q3 2016 results within normal time frame.  Full Article

Abbott Laboratories says "Alere’s lawsuit is without merit"
Friday, 26 Aug 2016 12:26pm EDT 

Abbott Laboratories : Abbott Laboratories says "Alere’s lawsuit is without merit" . Compliant with obligations under merger agreement with Alere . "continues to work toward regulatory approvals despite Alere’s nearly six month delay in filing its 2015 10-K" ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

More From Around the Web

BRIEF-Alere receives NYSE notice regarding late form 10-K filing

* Alere Inc receives NYSE notice regarding late form 10-K filing Source text for Eikon: Further company coverage: